Latest Articles

Publication Date
BBC star details 'intense and painful' health condition after collapsing during park run - Wales Online

BBC star details 'intense and painful' health condition after collapsing during park run Wales Online

Published: May 14, 2026, 12:32 p.m.
BBC star left 'on floor in intense pain' as she shares reality of debilitating condition - Glasgow Live

BBC star left 'on floor in intense pain' as she shares reality of debilitating condition Glasgow Live

Published: May 14, 2026, 12:32 p.m.
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete - AD HOC NEWS

Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS

Published: May 14, 2026, 12:26 p.m.
"My 30 year wait for an endometriosis diagnosis left me walking with a cane!" - ITVX

"My 30 year wait for an endometriosis diagnosis left me walking with a cane!" ITVX

Published: May 14, 2026, 11:52 a.m.
Karyopharm completes endometrial cancer trial enrollment - Investing.com

Karyopharm completes endometrial cancer trial enrollment Investing.com

Published: May 14, 2026, 11:52 a.m.
Karyopharm completes endometrial cancer trial enrollment By Investing.com - Investing.com Canada

Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada

Published: May 14, 2026, 11:45 a.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView

Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView

Published: May 14, 2026, 11:33 a.m.
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M - Stock Titan

Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan

Published: May 14, 2026, 11:30 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire

Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo

Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo

Published: May 14, 2026, 11:30 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!